Comparison of BNT162b2 (Pfizer-Biontech) and Mrna-1273 (moderna) SARS-CoV-2 Mrna Vaccine Immunogenicity in Dialysis Patients

Patients with end-stage renal disease undergoing dialysis are at very high risk of death in case of coronavirus disease 2019.1 Growing evidence suggests that a relatively high proportion of dialysis patients develops anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies after vaccination, albeit to a lesser extent than healthy controls.2 Here, we investigated whether there are differences in anti–SARS-CoV-2 antibody levels (directed against the receptor binding domain of the S1 subunit of the Spike [S] protein, measured with the SARS-CoV-2 IgG II Quant assay [Abbott]) in patients on hemodialysis without a history of SARS-CoV-2 infection after full vaccination (2 doses) with 1 of the 2 currently available mRNA vaccines (BNT162b2, Pfizer–BioNtech; or mRNA-1273, Moderna) against SARS-CoV-2, three weeks after administration of the second vaccine dose.